Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07QXU
|
||||
| Former ID |
DCL000900
|
||||
| Drug Name |
NS 2359
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Attention deficit hyperactivity disorder; Depression; Cocaine addiction [ICD9: 303-304, 304.2, 311, 314.00, 314.01; ICD10:F10-F19, F14.2, F32, F90] | Discontinued in Phase 2 | [1] | ||
| Company |
GlaxoSmithKline
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C15H19Cl2NO
|
||||
| Canonical SMILES |
COCC1C2CCC(N2)CC1C3=CC(=C(C=C3)Cl)Cl
|
||||
| InChI |
1S/C15H19Cl2NO/c1-19-8-12-11(7-10-3-5-15(12)18-10)9-2-4-13(16)14(17)6-9/h2,4,6,10-12,15,18H,3,5,7-8H2,1H3/t10-,11+,12+,15+/m0/s1
|
||||
| InChIKey |
FPTPUYCHSWIWIB-FUTJPDQTSA-N
|
||||
| CAS Number |
CAS 843660-54-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Dopamine reuptake | Target Info | Inhibitor | [2] | |
| Sodium-dependent serotonin transporter | Target Info | Inhibitor | [2] | ||
| Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [2] | ||
| KEGG Pathway | Serotonergic synapse | ||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | 5HT1 type receptor mediated signaling pathway | ||||
| 5HT2 type receptor mediated signaling pathway | |||||
| 5HT3 type receptor mediated signaling pathway | |||||
| 5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis | |||||
| Reactome | Na+/Cl- dependent neurotransmitter transporters | ||||
| WikiPathways | Monoamine Transport | ||||
| SIDS Susceptibility Pathways | |||||
| NRF2 pathway | |||||
| Synaptic Vesicle Pathway | |||||
| Serotonin Transporter ActivityWP727:Monoamine Transport | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| References | |||||
| REF 1 | Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. Epub 2008 Jan 2. | ||||
| REF 2 | Emerging drugs for attention-deficit/hyperactivity disorder. Expert Opin Emerg Drugs. 2007 Sep;12(3):423-34. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.